Endometrial Cancer
MK2870-033: A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)
- Details
ClinicalTrials.gov ID:
NCT06952504
Diagnosis Type:
NA
USOR Number:
- Address
,
P: